• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21959 Records] Selected Records [0 Hits] [Clear]
Year Source Title
1996     VA Technology Assessment Program (VATAP) Transferring managed care principles to VHA
2012     Penn Medicine Center for Evidence-based Practice (CEP) Transfer of neurointensive care patients
2002     Blue Cross Blue Shield Association (BCBS) Transesophageal endoscopic treatments for gastroesophageal reflux disease
2004     Blue Cross Blue Shield Association (BCBS) Transesophageal endoscopic treatments for gastroesophageal reflux disease
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Transdermally-delivered oxybutynin (Oxytrol(R)) for overactive bladder
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Transdermal hormone replacement therapy patches for women with postmenopausal symptoms: economic analysis of short-term use
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Transdermal contraceptive patch - a new birth control option
2022     Malaysian Health Technology Assessment (MaHTAS) Transcutaneous oxygen pressure monitoring (TcPO2)
2000     HAYES, Inc. Transcutaneous electrical nerve stimulation for the treatment of pain
2010     HAYES, Inc. Transcutaneous electrical nerve stimulation for postoperative and procedural pain
1995     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Transcutaneous electrical nerve stimulation and pain management - nonsystematic review
2006     HAYES, Inc. Transcutaneous electrical nerve stimulation (TENS) for the treatment of nausea and vomiting
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Transcutaneous electrical nerve stimulation (TENS-PENS) for back pain
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Transcutaneous electrical nerve stimulation (TENS-PENS) for back pain
2001     VA Technology Assessment Program (VATAP) Transcutaneous Electrical Nerve Stimulation
2000     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Transcutaneous bilirubinometry in the context of early postnatal discharge
2013     Institute of Health Economics (IHE) Transcutaneous bilirubinometry for the screening of neonatal hyperbilirubinemia ≥35 weeks' gestation
2010     HAYES, Inc. Transcutaneous bilirubin measurement
2012     HAYES, Inc. Transcription Factor 4 (TCF4) testing for Pitt-Hopkins Syndrome (PTHS)
2001     Norwegian Knowledge Centre for the Health Services (NOKC) Transcranial magnetic stimulation in the treatment of depressions
2008     Health Council of the Netherlands Gezondheidsraad (GR) Transcranial magnetic stimulation in psychiatry and neurology
2014     HAYES, Inc. Transcranial magnetic stimulation for treatment-resistant depression
2011     Blue Cross Blue Shield Association (BCBS) Transcranial magnetic stimulation for the treatment of schizophrenia
2021     Health Technology Wales (HTW) Transcranial magnetic stimulation for the treatment of depression
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcranial magnetic stimulation for the treatment of adults with PTSD, GAD, or depression: a review of clinical effectiveness and guidelines
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Transcranial magnetic stimulation for major depression and schizophrenia
2007     HAYES, Inc. Transcranial magnetic stimulation for major depression
2010     HAYES, Inc. Transcranial magnetic stimulation for major depression
2011     Blue Cross Blue Shield Association (BCBS) Transcranial magnetic stimulation for depression
2009     Blue Cross Blue Shield Association (BCBS) Transcranial magnetic stimulation for depression
2014     Blue Cross Blue Shield Association (BCBS) Transcranial magnetic stimulation for depression
2014     HAYES, Inc. Transcranial Magnetic Stimulation (TMS) to enhance pharmacotherapy for depression
2010     VA Technology Assessment Program (VATAP) Transcranial magnetic stimulation (TMS) for depression
2023     Austrian Institute for Health Technology Assessment (AIHTA) Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor
2016     Adelaide Health Technology Assessment (AHTA) Transcranial magnetic resonance-guided focused ultrasound and deep brain stimulation for refractory depression
2015     The Regional Health Technology Assessment Centre (HTA-centrum) Transcranial Magnetic Resonance Guided Focused Ultrasound treatment of essential tremor, neuropathic pain and Parkinson's disease
2009     Institute for Clinical Effectiveness and Health Policy (IECS) Transcranial doppler ultrasonography: main clinical applications
2013     Malaysian Health Technology Assessment (MaHTAS) Transcranial Doppler (TCD) ultrasound and cerebral computed tomography perfusion (CTP) for aneurysmal subarachnoid haemorrhage (SAH)
2017     HAYES, Inc. Transcranial direct current stimulation for depression
2014     HAYES, Inc. Transcranial direct current stimulation for depression
2009     NIHR Horizon Scanning Centre (NIHR HSC) Transcranial direct current stimulation (tDCS) for major depressive disorder
2009     NIHR Horizon Scanning Centre (NIHR HSC) Transcranial direct current stimulation (tDCS) for Alzheimer's disease
2007     HAYES, Inc. Transconjunctival sutureless vitrectomy using the Millennium TSV25 system (Bausch&Lomb Inc.)
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcendental meditation for posttraumatic stress disorder, depression, and anxiety: a review of clinical effectiveness
2022     Ontario Health Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2015     HAYES, Inc. Transcatheter surgical valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for aortic stenosis
2016     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Transcatheter occlusion of the left atrial appendage (LAA) for patients with non-valvular atrial fibrillation
2014     Medical Services Advisory Committee (MSAC) Transcatheter occlusion of the left atrial appendage (LAA) for patients with non-valvular atrial fibrillation
2015     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Transcatheter mitral valve replacement for severe mitral regurgitation
2021     Agency for Care Effectiveness (ACE) Transcatheter mitral valve leaflet repair for patients with mitral regurgitation
2016     Agenzia nazionale per i servizi sanitari regionali (Agenas) Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation
2010     National Institute for Health and Care Excellence (NICE) Transcatheter endovascular closure of perimembranous ventricular septal defect
2008     HAYES, Inc. Transcatheter closure of ventricular septal defects
2002     HAYES, Inc. Transcatheter closure of septal defects
2017     HAYES, Inc. Transcatheter closure of prosthetic aortic or mitral paravalvular leaks
2013     Medical Services Advisory Committee (MSAC) Transcatheter closure of patent ductus arteriosus
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Transcatheter closure of atrial septal defects
2006     Haute Autorite de sante (HAS) Transcatheter closure of a patent foramen ovale
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve replacement in severe aortic stenosis: a review of comparative durability and clinical effectiveness beyond 12 months
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve replacement in severe aortic stenosis: a review of comparative durability and clinical effectiveness beyond 12 months
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve replacement
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve implantation: a critical appraisal of a health technology assessment and comparison with a rapid review
2015     Medical Services Advisory Committee (MSAC) Transcatheter aortic valve implantation via transfemoral or transapical delivery
2020     Ontario Health Transcatheter Aortic Valve Implantation in Patients With Severe, Symptomatic Aortic Valve Stenosis at Intermediate Surgical Risk: A Health Technology Assessment
2020     Ontario Health Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk
2016     Health Quality Ontario (HQO) Transcatheter aortic valve implantation for treatment of aortic valve stenosis: OHTAC recommendation
2016     Health Quality Ontario (HQO) Transcatheter aortic valve implantation for treatment of aortic valve stenosis: a health technology assessment
2013     Health Quality Ontario (HQO) Transcatheter aortic valve implantation for the treatment of aortic valve stenosis: an evidence update
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve implantation for aortic stenosis: a review of the clinical effectiveness and guidelines
2012     HAYES, Inc. Transcatheter aortic valve implantation for aortic stenosis
2013     HAYES, Inc. Transcatheter aortic valve implantation for aortic stenosis
2011     Belgian Health Care Knowledge Centre (KCE) Transcatheter aortic valve implantation (TAVI): an updated health technology assessment
2021     Norwegian Institute of Public Health (NIPH) Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups: a health technology assessment
2013     Technology Assessment Unit of the McGill University Health Centre (MUHC) Transcatheter aortic valve implantation (TAVI) in patients with aortic stenosis. Update of Report No. 45
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
2018     European Network for Health Technology Assessment (EUnetHTA) Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
2012     Medical Advisory Secretariat (MAS) Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based analysis (Part B)
2013     Medical Advisory Secretariat (MAS) Transcatheter Aortic Valve Implantation (TAVI) for treatment of aortic valve stenosis: an evidence update
2020     Health Technology Wales (HTW) Transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis who are at intermediate surgical risk
2018     Agenzia nazionale per i servizi sanitari regionali (Agenas) Transcatheter aortic valve implantation (TAVI) for the treatment of patients at intermediate risk [EUnetHTA collaborative assessment OTCA06]
2011     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults. This evidence note updates evidence note 33 published in March 2011
2014     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults who are not eligible for surgery
2014     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults at high surgical risk
2011     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults
2021     Agency for Care Effectiveness (ACE) Transcatheter aortic valve implantation (TAVI) for patients with symptomatic severe aortic stenosis
2009     Technology Assessment Unit of the McGill University Health Centre (MUHC) Transcatheter Aortic Valve Implantation (TAVI) at the MUHC: a Health Technology Assessment
2012     New Zealand National Health Committee (NHC) Transcatheter Aortic Valve Implantation (TAVI) - briefing report
2020     Malaysian Health Technology Assessment (MaHTAS) Transbronchial cryobiopsy for lung biopsy in interstitial lung disease
2012     HAYES, Inc. Transarterial hepatic yttrium-90 radioembolization for treatment of unresectable intrahepatic cholangiocarcinoma
2013     HAYES, Inc. Transarterial embolization with embozene microspheres (CeloNova BioSciences Inc.) for treatment of hepatocellular carcinoma and other liver tumors
2012     HAYES, Inc. Transarterial chemoembolization plus radiofrequency ablation for liver cancer
2010     HTA Database, Centre for Reviews and Dissemination, University of York (CRD) Transarterial chemoembolization for palliation of unresectable liver metastases from colorectal cancer (Protocol for a systematic review)
2013     HAYES, Inc. Transanal hemorrhoidal dearterialization
2007     HAYES, Inc. Transanal endoscopic microsurgery for rectal carcinoma
2009     HAYES, Inc. Transanal endoscopic microsurgery for rectal carcinoma
2004     Medical Services Advisory Committee (MSAC) Transanal endoscopic microsurgery
2013     HAYES, Inc. Transabdominal Cervical Cerclage (TAC) for the prevention of miscarriage
2002     New Zealand Health Technology Assessment (NZHTA) Trans-gender reassignment surgery
2019     NIHR Health Technology Assessment programme Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Tranexamic acid for the management of bleeding: a review of the clinical effectiveness and guidelines